ABSTRACT Introduction Risankizumab, a selective inhibitor of the IL-23 p19 subunit, has shown efficacy in randomized trials in psoriatic arthritis (PsA); however, real-world data remain limited. We evaluated the effectiveness and treatment persistence of risankizumab in the GIRRCS cohort. Methods This observational stu...
Francesco Caso, E. Celletti, I. Pantano et al.· Expert Opinion on Biological...· 0 citations
Abstract Janus kinase (JAK) inhibition is an established therapeutic strategy in rheumatoid arthritis, but heterogeneous treatment responses, persistent safety concerns, and the need for more precise therapeutic positioning continue to stimulate the development of additional JAK-directed compounds. This structured narr...
Luisa Costa, Francesco Caso, F. Maione et al.· Drug Design, Development and...· 0 citations
ABSTRACT Introduction Still’s disease is a systemic inflammatory disorder characterized by a complex cytokine network involving interleukin (IL)-1, IL‑6, IL‑18 and interferon (IFN)-γ. Although IL‑1 and IL‑6 inhibitors represent the cornerstone of current targeted therapy, a subset of patients remains refractory or deve...
P. Ruscitti, F. Ursini, R. Giacomelli et al.· Expert Opinion on Pharmacoth...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
